No products in the cart
Mod GRF 1-29 & GHRP-6 (10mg)
Mod GRF 1-29 & GHRP-6 blend is Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Mod GRF (1-29) & GHRP-6 peptide blend?
Mod GRF (1-29) & GHRP-6 are two synergistic peptides. These peptides appear to work together effectively to increase the release of growth hormone (GH). The full structure of Growth Hormone Releasing Hormone (GHRH) contains 44 amino acids. Researchers have noticed that the first 29 amino acids (1-29) contain the full biological activity of GHRH. This fraction is called Growth Hormone Releasing Factor (GRF 1-29). GRF 1-29 appears to be biologically more active and has a longer duration of action as it evades metabolic clearance. Similarly, Growth Hormone Releasing Peptide-6 (GHRP-6) is under study as a potent stimulator of growth hormone release from the anterior pituitary gland. According to the researchers “These results provide evidence that the GH-stimulatory effects of GHRP-6 are achieved through activation of the PI second messenger system and thus support earlier findings that PKC and Ca2+ play central roles in mediating the effects of GHRP-6.”
Using a blend of Mod GRF (1-29) & GHRP-6 may lead to superior growth hormone release and better outcomes than using either of these peptides alone.
Modified GRF (1-29) Specifications
MOLECULAR FORMULA: C152H252N44O42
MOLECULAR WEIGHT: 3367.95 g/mol
CAS NUMBER: 863288-34-0
PUBCHEM: CID 56841945
MOLECULAR FORMULA: C46H56N12O6
MOLECULAR WEIGHT: 873.032 g/mol
CAS NUMBER: 87616-84-0
SEQUENCE: L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysergamide, triacetate
PUBCHEM: CID 9919153
Research on Mod GRF (1-29) & GHRP-6
Mod GRF (1-29) & GHRP-6 Peptides and Brain Health
Mod GRF (1-29) and GHRP-6 has the potential to help improve mental health and improve neurodegenerative conditions. This could be particularly useful in conditions such as Alzheimer’s and Parkinson’s disease. The peptide blend is also being studied for its potential to affect overall mental well-being and vitality, and for its viability to be used in conditions such as depressive disorders. GHRP-6 may also help with memory improvement and better learning. Studies in rodents reported that using GHRP-6 appeared to help retain more memories and aid in turning short-term memories into long-term memories. Research also suggests that GH analogs, such as GHRP-6, can assist spatial learning. GHRP-6 could be useful in situations such as acute stroke, as it may provide improved functional aspects of brain function, such as spatial learning, problem-solving, and creating thinking. Research suggests that using GHRP-6 and other ghrelin analogs may improve the supply of blood to the brain. This would prevent the development of new strokes and improve recovery following established strokes by reducing infarct size and promoting new tissue development. Mod GRF (1-29) & GHRP-6 blend could help reduce apoptosis in brain cells, lower inflammation, and prevent age-related structural and functional decline in brain function.
Mod GRF (1-29) & GHRP-6 Peptides and Anti-Aging
The levels of growth hormone peak during the early teenage years and decline after that. The aging process is a direct consequence of declining levels of growth hormone. Many anti-aging treatments and processes aim to naturally increase the levels of growth hormones in the body. The synergy of Mod GRF (1-29) and GHRP-6 appear to naturally increase growth hormone levels and thereby reverse the aging processes. This reversal is mostly due to the potential ability of these peptides to boost cellular repair, reduce cellular damage due to oxidative stress, and reduce telomere shortening.
Mod GRF (1-29) & GHRP-6 Peptides and Wound Healing
Mod GRF (1-29) & GHRP-6 in combination appears to increase tissue synthesis and promote wound healing. GHRP-6 interacts with CD36 receptors known to promote angiogenesis, which is the growth of new blood vessels. The researchers report that “In covalent competition binding studies with the GHRP-6 prototype hexarelin bearing a radiotracer, certain [aza-Glu]GHRP-6 azapeptides retained relatively high (2-27 μM) affinity for the CD36 scavenger receptor.” The growth of new blood vessels in wounds improves wound healing. Animal studies have observed that GHRP-6 appears to improve wound closure, increasing the synthesis of extracellular proteins like collagen, and stimulating scar formation. This potential ability of this peptide blend may eventually be used in clinical practice to achieve superior aesthetic outcomes in cosmetic surgeries.
Mod GRF (1-29) & GHRP-6 Peptides and Heart Disease
Oxidative stress results in increased Reactive Oxygen Species (ROS) that damage the heart tissues and can result in heart damage. Research suggests that GH analogs such as Mod GRF (1-29) and GHRP-6 may reduce the levels of oxidative stress, lower the risk of heart attacks, and protect vulnerable but still viable cells. These peptides may also improve cardiovascular health by promoting a healthy lipid profile, including increased triglyceride breakdown.
Mod GRF (1-29) & GHRP-6 Peptides and Muscle Growth
Muscle growth is one of the most studied effects of growth hormones. Growth hormone analogs such as Mod GRF (1-29) & GHRP-6 have been studied for their potential to increase muscle mass via two different mechanisms: muscle hypertrophy and hyperplasia. Muscle hypertrophy results in increased muscle mass due to the increased size of already present muscle fibers. Muscle hyperplasia increases muscle mass by increasing the number of muscle fibers.
Mod GRF (1-29) & GHRP-6 Peptides and Bone Development
Growth hormone analogs appear to mediate many of their effects on bone mass via Insulin-Like Growth Factor 1 (IGF-1). IGF-1 promotes the growth, differentiation, and survival of bone-forming cells. IGF-1 improves the mineralization of bones and increases bone mineral density. In addition, it also prevents the excessive hormone-induced loss of bones. This way, GH/IGF-1 interplay improves bone quality and reduces the risk of conditions such as osteoporosis.
To conclude, the Mod GRF (1-29) & GHRP-6 peptide blend may have various clinical and biological effects. This blend appears to increase the levels of the GH/IGF-1 axis. It has been observed to exhibit cellular proliferating and cytoprotective activities. This blend been studied for its potential protective effects against cellular damage resulting from increasing inflammation and oxidative stress. Moreover, this blend may increase cellular proliferation and improve healthy tissue healing.
- Youn YS, Lee KC. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12). Bioconjug Chem. 2007 Mar-Apr;18(2):500-6. doi: 10.1021/bc060173z. Epub 2007 Jan 23. PMID: 17243755.
- Lei T, Buchfelder M, Fahlbusch R, Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Mol Endocrinol. 1995 Feb;14(1):135-8. doi: 10.1677/jme.0.0140135. PMID: 7772238.
- Subirós N, Pérez-Saad HM, Berlanga JA, Aldana L, García-Illera G, Gibson CL, García-Del-Barco D. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95. doi: 10.1179/1743132815Y.0000000089. Epub 2016 Apr 19. PMID: 26311576.
- Sabatino D, Proulx C, Pohankova P, Ong H, Lubell WD. Structure-activity relationships of GHRP-6 azapeptide ligands of the CD36 scavenger receptor by solid-phase submonomer azapeptide synthesis. J Am Chem Soc. 2011 Aug 17;133(32):12493-506. doi: 10.1021/ja203007u. Epub 2011 Jul 21. PMID: 21692501.
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.